Chemistry:Braegen-02
From HandWiki
Braegen-02 is a small-molecule drug which acts as a potent and selective agonist of the tropomyosin receptor kinase B (TrkB). It is commonly referred to as CF3CN due to the CF3 and CN groups in its chemical structure, but this may cause confusion with the unrelated chemical trifluoroacetonitrile which has the chemical formula CF3CN. As with many TrkB agonists it was derived through modification of the natural product TrkB agonist 7,8-dihydroxyflavone, but it is more potent than earlier derivatives such as R13. It is under development as a potential treatment for neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease.[1][2][3][4]
See also
- Tropomyosin receptor kinase B § Agonists
- BrAD-R13 (Braegen-01)
References
- ↑ "Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease". Neuropharmacology 197. October 2021. doi:10.1016/j.neuropharm.2021.108737. PMID 34343610.
- ↑ "Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase". Neurotherapeutics 19 (4): 1283–1297. July 2022. doi:10.1007/s13311-022-01248-1. PMID 35595958.
- ↑ "Zein-Based Nanoparticles Improve the Therapeutic Efficacy of a TrkB Agonist toward Alzheimer's Disease". ACS Chemical Neuroscience 14 (17): 3249–3264. September 2023. doi:10.1021/acschemneuro.3c00401. PMID 37583253.
- ↑ "TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury". Life Sciences 336. January 2024. doi:10.1016/j.lfs.2023.122282. PMID 38008209.
 |  |
